With so many blue chip ASX 200 shares to choose from, it can be hard to decide which ones to buy over others.
To help narrow things down, I have picked out two that experts rate as buys right now. They are as follows:
CSL Limited (ASX: CSL)
The first blue chip ASX 200 share to consider is CSL. It is one of the world's leading biotechnology companies, comprising the CSL Behring, CSL Vifor, and Seqirus businesses.
Combined, these businesses have a portfolio filled to the brim with life-saving therapies and vaccines. In addition, they all have burgeoning research and development (R&D) pipelines with potentially lucrative therapies to drive future growth. This is underpinned by CSL's decision to reinvest approximately 10% of sales into R&D activities each year. This is a significant number and led to an investment of approximately US$1 billion in FY 2022.
Another positive that bodes well for the company's performance in the coming years is the recent major improvements in plasma collections and the company's new collection technology. The latter is expected to collect plasma more efficiently and deliver stronger yields.
Citi is positive on CSL and currently has a buy rating and $340.00 price target on its shares.
Woolworths Limited (ASX: WOW)
Another blue chip option to consider is Woolworths. It is of course the retail conglomerate behind businesses including Woolworths, Countdown, Everyday Rewards, and Big W.
It has been tipped as a buy by analysts at Goldman Sachs. They believe its shares are trading at an attractive level after recent weakness. Particularly given its digital and omni-channel advantage, which the broker expects to drive further market share and margin gains.
In fact, Goldman Sachs is so positive it has put the company on its coveted conviction list. It currently has a conviction buy rating and $44.10 price target on the company's shares.
Another positive is that the broker is forecasting fully franked dividend yields of 3%+ in the coming years.
